Assessing safety and efficacy of directed P-glycoprotein inhibition to improve the pharmacokinetic properties of saquinavir coadministered with ritonavir

Journal of Pharmacology and Experimental Therapeutics

Volumn 304, Issue 2, 2003, Pages 596-602

  Huisman, Maarten T ^a   Smit, Johan W ^b   Wiltshire, Hugh R ^c   Beijnen, Jos H ^d   Schinkel, Alfred H ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b Cobra Therapeutics Limited ^*  (United Kingdom)

^c ROCHE PRODUCTS LTD   (United Kingdom)

^d SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ELACRIDAR; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; PROTEIN INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; DRUG UPTAKE; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; STOMACH EMPTYING;

ACRIDINES; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; DRUG THERAPY, COMBINATION; FEMALE; ISOQUINOLINES; MALE; MICE; MICE, KNOCKOUT; P-GLYCOPROTEIN; P-GLYCOPROTEINS; PREGNANCY; RITONAVIR; SAQUINAVIR; TETRAHYDROISOQUINOLINES;

EID: 0037307995     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.044388     Document Type: Article

References (39)

1. Alsenz J, Steffen H, and Alex R (1998) Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 Cell monolayers. Pharm Res (NY) 15:423-428.
2. Bardelmeijer HA, Beijnen JH, Brouwer KR, Rosing H, Nooijen WJ, Schellens JHM, and van Tellingen O (2000) Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. Clin Cancer Res 6:4416-4421.
3. Cameron DW, Japour AJ, Xu Y, Hsu A, Mellors J, Farthing C, Cohen C, Poretz D, Markowitz M, Follansbee S, et al. (1999) Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS 13:213-224.
4. Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, and Kim RB (2000) Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 28:655-660.
5. Chun TW and Fauci AS (1999) Latent reservoirs of HIV: obstacles to the eradication of virus. Proc Natl Acad Sci USA 96:10958-10961.
6. Cummins CL, Jacobsen W, and Benet LZ (2002) Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 300:1036-1045.
7. Dresser GK, Spence JD, and Bailey DG (2000) Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 38:41-57.
8. Drewe J, Gutmann H, Fricker G, Torok M, Beglinger C, and Huwyler J (1999) HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem Pharmacol 57:1147-1152.
9. Eagling VA, Back DJ, and Barry MG (1997) Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 44:190-194.
10. Eisen SA, Miller DK, Woodward RS, Spitznagel E, and Przybeck TR (1990) The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 150:1881-1884.
11. Fitzsimmons ME and Collins JM (1997) Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism. Drug Metab Dispos 25:256-266.
12. Gatti G, Di Biagio A, Casazza R, De Pascalis C, Bassetti M, Cruciani M, Vella S, and Bassetti D (1999) The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring. AIDS 13:2083-2089.
13. Gottesman MM and Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385-427.
14. Guengerich FP (1999) Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39:1-17.
15. Gutmann H, Fricker G, Drewe J, Toeroek M, and Miller DS (1999) Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol Pharmacol 56:383-389.
16. Higgins CF (1992) ABC transporters: from microorganisms to man. Annu Rev Cell Biol 8:67-113.
17. Holash JA, Harik SI, Perry G, and Stewart PA (1993) Barrier properties of testis microvessels. Proc Natl Acad Sci USA 90:11069-11073.
18. Huisman MT, Smit JW, Wiltshire HR, Hoetelmans RMW, Beijnen JH, and Schinkel AH (2001) P-glycoprotein limits oral availability, brain and fetal penetration of saquinavir even with high doses of ritonavir. Mol Pharmacol 59:806-813.
19. Hyafil F, Vergely C, Du Vignaud P, and Grand-Perret T (1993) In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 53:4595-4602.
20. Jordan WC (1998) The effectiveness of combined saquinavir and ketoconazole treatment in reducing HIV viral load. J Natl Med Assoc 90:622-624.
21. Juliano RL and Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152-162.
22. Kaufmann GR, Duncombe C, Cunningham P, Beveridge A, Carr A, Sayer D, French M, and Cooper DA (1998) Treatment response and durability of a double protease inhibitor therapy with saquinavir and ritonavir in an observational cohort of HIV-1-infected individuals. AIDS 12:1625-1630.
23. Kim AE, Dintaman JM, Waddell DS, and Silverman JA (1998a) Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J Pharmacol Exp Ther 286:1439-1445.
24. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, and Wilkinson GR (1998b) The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Investig 101:289-294.
25. Koudriakova T, Iatsimirskaia E, Utkin I, Gangl E, Vouros P, Storozhuk E, Orza D, Marinina J, and Gerber N (1998) Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab Dispos 26:552-561.
26. Malingré MM, Beijnen JH, Rosing H, Koopman FJ, Jewell RC, Paul EM, Huinink WW, and Schellens JH (2001) Coadministration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. Br J Cancer 84:42-47.
27. Meaden ER, Hoggard PG, Newton P, Tjia JF, Aldam D, Cornforth D, Lloyd J, Williams I, Back DJ, and Khoo SH (2002) P-Glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals. J Antimicrob Chemother 50:583-588.
28. Perry CM and Noble S (1998) Saquinavir soft-gel capsule formulation. A review of its use in patients with HIV infection. Drugs 55:461-486.
29. Polli JW, Jarrett JL, Studenberg SD, Humphreys JE, Dennis SW, Brouwer KR, and Woolley JL (1999) Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm Res (NY) 16:1206-1212.
30. Schinkel AH, Mayer U, Wagenaar E, Mol CAAM, van Deemter L, Smit JJ, van der Valk MA, Voordouw AC, Spits H, van Tellingen O, et al. (1997) Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 94:4028-4033.
31. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CAAM, van der Valk MA, Robanus-Maandag EC, and te Riele HP (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502.
32. Smit JW, Huisman MT, van Tellingen O, Wiltshire HR, and Schinkel AH (1999) Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J Clin Investig 104:1441-1447.
33. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DKF, Borst P, Nooijen WJ, Beijnen JH, and van Tellingen O (1997) Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94:2031-2035.
34. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, and Willingham MC (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84:7735-7738.
35. Van der Sandt I, Vos CM, Nabulsi L, Blom-Roosemalen MC, Voorwinden HH, de Boer AG, and Breimer DD (2001) Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood-brain barrier. AIDS 15:483-491.
36. Van Heeswijk RPG, Hoetelmans RMW, Harms R, Meenhorst PL, Mulder JW, Lange JM, and Beijnen JH (1998) Simultaneous quantitative determination of the HIV protease inhibitors amprenavir, indinavir, nelfinavir, ritonavir and saquinavir in human plasma by ion-pair high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl 719:159 -168.
37. Wandel C, Kim RB, Kajiji S, Guengerich P, Wilkinson GR, and Wood AJ (1999) P-Glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res 59:3944-3948.
38. Washington CB, Wiltshire HR, Man M, Moy T, Harris SR, Worth E, Weigl P, Liang Z, Hall D, Marriott L, and Blaschke TF (2000) The disposition of saquinavir in normal and P-glycoprotein-deficient mice, rats and in cultured cells. Drug Metab Dispos 28:1058-1062.
39. Williams GC and Sinko PJ (1999) Oral absorption of the HIV protease inhibitors: a current update. Adv Drug Deliv Rev 39:211-238.